CTIS2023-507700-32-00进行中（未招募）1 期
PRSCK-21P01
Peaches Biotech S.L.0 个研究点目标入组 50 人开始时间: 2023年10月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced MelanomaMetastatic MelanomaMedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104CTIS2024-511949-19-00Sairopa B.V.44
进行中（未招募）
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Overweight, ObesityMedDRA version: 20.0Level: PTClassification code: 10033307Term: Overweight Class: 100000004861MedDRA version: 20.0Level: PTClassification code: 10029883Term: Obesity Class: 100000004861CTIS2023-507758-34-00Rose Pharma Inc.12
进行中（未招募）
1 期
A phase Ia, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) in healthy adultsCTIS2024-511266-36-00niversitaetsklinikum Tuebingen AöR72
进行中（未招募）
1 期
A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktailHereditary angioedemaCTIS2024-514713-35-0014
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of Prosetin in Healthy Volunteers and Participants with Amyotrophic Lateral Sclerosis (ALS) with an Optional Open-Label Extended Treatment Period for ALS Participants who Complete 14 Days of Blinded TreatmentCTIS2023-507363-20-00Projenx Inc.24